Cognition Therapeutics Inc (CGTX): Total Liabilities
$14.12M
As of 2025-12-31
$5.87M
As of 2026-06-30
+11.5%
3-year compound annual growth
-6.7%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $14.12M | +22.9% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $11.48M | +7.4% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $10.69M | +5.0% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $10.18M | +29.4% | 2024-03-26, Balance as of period end |
| 2021-12-31 | $7.86M | -60.5% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $19.93M | n/a | 2022-03-30, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Cognition Therapeutics Inc (CGTX) | 2025-12-31 | $14.12M | +22.9% |
| PharmaCyte Biotech, Inc. (PMCB) | 2026-04-30 | $11.77M | +259.2% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $45.63M | -3.1% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | $55.68M | +5.4% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $74.01M | -6.2% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $16.50M | +15.8% |
| Passage BIO, Inc. (PASG) | 2025-12-31 | $43.53M | +5.8% |
| Elutia Inc. (ELUT) | 2025-12-31 | $34.68M | -57.9% |
| Jasper Therapeutics, Inc. (JSPR) | 2025-12-31 | $31.63M | +73.5% |
Compare CGTX, PMCB, SNTI, OCGN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗